Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce osteolytic bone lesions. Bone destruction in MM mainly depends on the increase of osteoclast formation and activity that occurs in close contact with myeloma cells infiltration. The histomorphometric studies, performed in MM patients, have demonstrated that MM patients with high plasma cell infiltrate are also characterized by a lower number of osteoblasts and a decreased bone formation that contributes, to the development of bone lesion. In the last years the progress in acknowledge of the pathophysiology of MM-induced osteolysis leaded to identify new therapeutics targets in MM bone disease and developed new drugs in the treatment of patients with skeletal involvement
Keywords: Multiple Myeloma, osteoclast, RANKL, osteoblast, drugs
Current Pharmaceutical Biotechnology
Title: Targeting Pathways Mediating Bone Disease
Volume: 7 Issue: 6
Author(s): Nicola Giuliani, Francesca Morandi, Sara Tagliaferri and Vittorio Rizzoli
Affiliation:
Keywords: Multiple Myeloma, osteoclast, RANKL, osteoblast, drugs
Abstract: Multiple myeloma (MM) is a plasma cell malignancy characterized by the high capacity to induce osteolytic bone lesions. Bone destruction in MM mainly depends on the increase of osteoclast formation and activity that occurs in close contact with myeloma cells infiltration. The histomorphometric studies, performed in MM patients, have demonstrated that MM patients with high plasma cell infiltrate are also characterized by a lower number of osteoblasts and a decreased bone formation that contributes, to the development of bone lesion. In the last years the progress in acknowledge of the pathophysiology of MM-induced osteolysis leaded to identify new therapeutics targets in MM bone disease and developed new drugs in the treatment of patients with skeletal involvement
Export Options
About this article
Cite this article as:
Giuliani Nicola, Morandi Francesca, Tagliaferri Sara and Rizzoli Vittorio, Targeting Pathways Mediating Bone Disease, Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116955
DOI https://dx.doi.org/10.2174/138920106779116955 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress on Fucosyltransferase Inhibitors
Mini-Reviews in Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry Targeting Bcl-2 Family of Proteins: An Important Strategy in Cancer Therapeutics
Current Chemical Biology Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Editorial (Thematic Issue: Chronic Myeloid Leukemia: Reaching For the Cure)
Current Cancer Drug Targets Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Current Cancer Drug Targets The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry